ABSTRACT
Non-small cell lung cancer (NSCLC) is the most common pathological type of primary lung cancer. Currently, main treatment approaches for NSCLC patients include surgical resection, radiotherapy, chemotherapy, targeted therapy and so on. In recent years, thermal ablation has received increasing attention in the treatment of various stages of NSCLC. As a safe and efficient local treatment, thermal ablation may bring potential clinical benefits to NSCLC patients. However, many issues remain unsolved and further investigation is needed in the clinical application of thermal ablation in NSCLC. In this review, we aim to summarize the applications of thermal ablation in NSCLC and further discuss the emerging controversies as well as future research directions.
ABSTRACT
BACKGROUND: Although patients with EGFR-mutant non-small-cell lung cancer (NSCLC) benefit from treatment with EGFR-tyrosine kinase inhibitors (TKIs), outcomes are limited by the eventual development of acquired resistance. We conducted a retrospective study to evaluate the efficacy and feasibility of EGFR-TKI therapy beyond focal progression, associated with microwave ablation. METHODS: Patients with metastatic EGFR-mutant NSCLC treated with EGFR-TKIs at our institutions from May 2012 to December 2017 were identified. Patients with single lesion progression, treated with MWA, and continually administered EGFR-TKI therapy until further progression, were included in the study. Initial response to target therapy, median progression-free survival (PFS1), and first progression site were recorded. The median time to progression after local therapy (PFS2) was also assessed. Overall survival was calculated from the initiation of EGFR-TKIs to the date of final follow-up or death. RESULTS: Fifteen out of 205 patients (10%) satisfied the inclusion criteria. Local therapy was well tolerated, and complete ablation was performed in 11 (73.3%) patients. The median PFS1 was 9.5 months (range 6-41), and the median PFS2 was 8 months (range 3-24). The corresponding 6 and 12 month PFS rates were 73.3% and 26.7%, respectively. Median overall survival was 23 months (range 15-64). CONCLUSION: The longer disease control observed in our patients suggests that continuation of EGFR-TKI beyond focal progression associated to microwave ablation is an efficacious therapeutic strategy.
Subject(s)
Carcinoma, Non-Small-Cell Lung/therapy , Lung Neoplasms/therapy , Protein Kinase Inhibitors/administration & dosage , Radiofrequency Ablation/methods , Adult , Aged , Aged, 80 and over , Carcinoma, Non-Small-Cell Lung/genetics , Combined Modality Therapy , ErbB Receptors/antagonists & inhibitors , ErbB Receptors/genetics , Female , Humans , Lung Neoplasms/genetics , Male , Microwaves , Middle Aged , Mutation , Protein Kinase Inhibitors/therapeutic use , Retrospective Studies , Survival Analysis , Treatment OutcomeABSTRACT
Simultaneous phenotyping of AHSG, Pi and GC by IEF is reported. The results showed that the cumulative discrimination power and the cumulative exclusion probability of paternity of this method were 0.9701 and 0.58.11 respectively. It was proved to be the most efficient method for individual identification among the simultaneous phenotypings of genetic markers.It has been applied to paternity test and the results were satisfactory.
ABSTRACT
This paper reports the detection of G2m(n)factors in human sera using theenzyme-linked immunosorbent inhibition test with monoclonal antibodies agai-nst G2m(n)factor(SH-21).The gene freguency of G2m(n)factor among 517unrelated individuals of ban population in Chengeu area was 0.5493 and itsvariance was 0.0004.
ABSTRACT
A PAGE IEF immunoassay was established to detect the ORM, Pi, AHSG and GC phenotypes slmultaneously in human bloodstains. The cumulative discriminating power and probability of paternity exclusion were 0. 9878 and 0. 6648 respectively. Human sera diluted 100 times and bloodstains kept at room temperature for 4 weeks could be typed for these four blood groups correctly. The phenotypes of ORM, AHSG and GC could be determined correctly in bloodstains kept at room temperature within 24 weeks. This provides a good approach for individual identification of human bloodstains.
ABSTRACT
?-1 acid glycoprotein, also named orosomucoid (ORM), is one kind of serum protein with genetic polymorPhism. Anti-ORM serum is necessary to phenotyping ORM. This communication describes the preparation of the antiORM serum. The anti-ORM sera were produced in three New Zealand rabbits cimmunized with ORM which was isolated and purified from human sera previously in our laboratory. The results of identification showed that the specificity of the home made anti-ORM and the commercial anti-ORM sera (Sigma) were identical. The titer of the home made anti-ORM serum was 128. 2.4?g/ml ORM could be detected by double immunodiffusion with the anti-ORM serum. In addition, the anti-ORM serum did not cross-react with other human serum proteins.
ABSTRACT
Identification of the human semen stain is reported using the latex particle agg-lutination inhibition test.The latex particles were coated with the human seminalplasma.The raw antihuman semen sera were previously absorbed with the humancolostrum.The results indicated that this method was more sensitive and acc-urate than sperm detection method.The sensitivty and the accuracy of the latex-particle agglutination inhibition test is the same as those of the double immunodiffusion test-using anti-p30 serum.Moreover,this method is easy to porform,nottime consuming and more practical.
